Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.

ABSTRACT: Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with approximately four new cases per 100,000 persons per year. Standard treatment for AML consists of induction chemotherapy with remission achieved in 50 to 75% of cases. Unfortunately, most patients will relapse and die from their disease, as 5-y survival is roughly 29%. Therefore, other treatment options are urgently needed. In recent years, immune-based therapies have led to unprecedented rates of survival among patients with some advanced cancers. Suppression of T cell function in the tumor microenvironment is commonly observed and may play a role in AML. We found that there is a significant association between T cell infiltration in the bone marrow microenvironment of newly diagnosed patients with AML and incr

SUBMITTER: Lamble AJ 

PROVIDER: S-EPMC7321988 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature